Key Takeaway: Celldex Therapeutics, Inc. announced its participation in the SVB Securities Global Biopharma Conference, scheduled for February 15, 2023. The company will host a fireside chat at 9:20 AM ET, which will be accessible via a webcast on their website. The event highlights Celldex's commitment to transparency and investor relations as it advances its pipeline of innovative therapies targeting serious diseases. A replay of the presentation will be available for 90 days post-event.
Price reaction · baseline $42.58 (2023-02-14 close) · hit after-hours · 2 other CLDX headline(s) in the window, move may be shared
day 0 close · peak
+0.7%
Market Sentiment Analysis
POSITIVE FACTORS
Celldex is actively engaging with investors through a presentation.
Participation in a prominent biopharma conference emphasizes its growth prospects.
The company is focused on developing impactful treatments for serious diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
6.2%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
barzolvolimab
Phase 3 · Chronic Inducible Urticaria
Full Press Release Details
HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma Conference today at 9:20 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.